Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
This is the official patient information website for ambrisentan (brand name Letairis), the original pulmonary arterial hypertension treatment drug developed by Gilead Sciences, USA. The domain name pahinformation corresponds to the abbreviation of Pulmonary Arterial Hypertension. The core of the site is to provide official drug information and safe medication guidance for patients in the United States, while also introducing the patient co-pay assistance program for the brand-name drug. This drug is an FDA-approved prescription medication used to treat pulmonary arterial hypertension, slow disease progression, and improve patients' exercise capacity.
The core content of the site includes complete drug indication descriptions, detailed safety warnings and adverse reaction introductions, contraindications and precautions for use. It also has a dedicated section that provides cost assistance information for patients: eligible US patients with commercial insurance can participate in the co-pay coupon program, where the minimum out-of-pocket cost is only $5 per month, and the program provides up to $20,000 in annual assistance, greatly reducing the medication burden for eligible patients. The site also separates entry portals for general patients and healthcare professionals, providing dedicated prescription information resources for medical staff.
This site is only intended for eligible patients located in the United States and its territories, and does not offer its assistance programs to Chinese users. It can only serve as reference information for Chinese pulmonary arterial hypertension patients. The site itself can be accessed directly without any connection tools, but it only provides English content and has no Chinese localization support.
Overall, this site is a compliant, professional official information platform for the original drug, with authoritative and reliable information. However, it has clear restrictions on its service scope, so it has limited practical value for domestic users in China.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on pahinformation.com official site.
pahinformation.com is an United States Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach pahinformation.com directly.